Abstract
In the early era of COVID-19, characterization of long-term complications was unfeasible. But in early 2021, the authors came across a patient with a new diagnosis of Acute Myeloid Leukemia (AML) that was highly suspected as being secondary to a previous COVID-19 infection. The similarities of this anomaly to Hodgkin Lymphoma occurring after Epstein Barr Virus prompted the authors to perform a qualitative review of the literature for a possible pathway of how COVID-19 can cause AML.